Released Aug 12, 2025, after the close
10-Q filed Aug 12, 2025, 43 days after period end · 0001390478-25-000016
Q2 2025 · 10-Q
Revenue—
Net Income-$6.60M-$6.60M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.07-$0.07 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$6,873,000N/M
Operating Cash Flowderived-$7,330,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 |
| Net Income | -$6.60M | -$7.47M | -$8.84M | -$8.41M |
| EPS Diluted | -$0.07 | -$0.13 | -$0.31 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR